| 利妥昔单抗在血液系统临床应用研究新进展 |
| |
| 引用本文： | 张洁. 利妥昔单抗在血液系统临床应用研究新进展[J]. 中国新药杂志, 2005, 14(12): 1481-1485 |
| |
| 作者姓名： | 张洁 |
| |
| 作者单位： | 天津医科大学附属肿瘤医院,天津,300060 |
| |
| 摘 要： | 利妥昔单抗为人鼠嵌合型单克隆抗体,已被FDA批准用于复发或难治性的CD20阳性的B细胞低度恶性或滤泡型非霍奇金淋巴瘤(NHL)的治疗.它能特异性结合B淋巴细胞表面CD20抗原,杀伤体内的B淋巴细胞.临床主要用于治疗各种一线或二线B细胞NHL,可以单独应用,亦可与化疗药物联合应用,目前还尝试用于慢性淋巴细胞白血病、多发性骨髓瘤、特发行血小板减少性紫癜等的治疗.
|
| 关 键 词： | 利妥昔单抗 非霍杰金淋巴瘤 慢性淋巴细胞白血病 多发性骨髓瘤 |
| 文章编号： | 1003-3734（2005）12-1481-05 |
| 修稿时间： | 2005-06-30 |
Rituximab in the treatment of blood diseases |
| |
| ZHANG Ji. Rituximab in the treatment of blood diseases[J]. Chinese Journal of New Drugs, 2005, 14(12): 1481-1485 |
| |
| Authors: | ZHANG Ji |
| |
| Affiliation: | Cancer Hospital Affiliated to Tianjin University of Medicine, Tianjin 300060, China |
| |
| Abstract: | The mouse/human chimeric anti-CD20 Moab mabthera(rituximab) has been approved by the US Food and Drug Administration for the treatment of relapsed and refractory advanced follicular non-Hodgkin's lymphoma.Rituximab targets the CD20 cell surface protein present on mature B cells and most B-cell malignancies.Rituximab has clinically used for various B-cell lymphomas as either first/second line single or combined regimen with other chemotherapies.Other clinical therapies against chronic lymphocytic leukemia,multiple myeloma,idiopathic thrombocytopenic purpura with rituximab are ongoing in the clinical studies settings. |
| |
| Keywords: | rituximab monoclonal antibody non-Hodgkin's lymphoma chronic lymphocytic leukemia multiple myeloma |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
